{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:52:44Z","timestamp":1763765564184},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.pcad.2005.06.007","type":"journal-article","created":{"date-parts":[[2005,11,16]],"date-time":"2005-11-16T14:31:51Z","timestamp":1132151511000},"page":"108-124","source":"Crossref","is-referenced-by-count":9,"title":["Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation"],"prefix":"10.1016","volume":"48","author":[{"given":"Alan S.","family":"Go","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2005.06.007_bib1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2005.06.007_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(96)00559-0","article-title":"Epidemiology and mechanism of atrial fibrillation and atrial flutter","volume":"78","author":"Camm","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1212\/WNL.40.7.1046","article-title":"Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: The Lausanne Stroke Registry","volume":"40","author":"Bogousslavsky","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2005.06.007_bib5","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2005.06.007_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation study. Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian Atrial Fibrillation Anticoagulation (CAFA) study","volume":"18","author":"Connolly","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib10","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib12","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.292.15.1867","article-title":"Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease","volume":"292","author":"Tran","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European stroke prevention study 2: Dipyridamole and acetylsalicylic acid in the prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.pcad.2005.06.007_bib15","first-page":"112","article-title":"Letter to the editor","volume":"153","author":"Diener","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.pcad.2005.06.007_bib16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.158.14.1513","article-title":"Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation study (the AFASAK2 study)","volume":"158","author":"Gullov","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation study: Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-8703(99)70259-0","article-title":"Alternate-day dosing of aspiring in atrial fibrillation. LASAF Pilot Study Group","volume":"138","author":"Posada","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.pcad.2005.06.007_bib19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/0002-8703(92)90074-6","article-title":"The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"124","author":"Singer","year":"1992","journal-title":"Am. Heart J."},{"key":"10.1016\/j.pcad.2005.06.007_bib20","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/bmj.319.7215.958","article-title":"Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin","volume":"319","author":"Hellemons","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2005.06.007_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2004.05.084","article-title":"Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study","volume":"44","author":"Perez-Gomez","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.154.13.1449","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archinte.157.11.1237","article-title":"The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators","volume":"157","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib26","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archinte.1997.00440320143013","article-title":"The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials","volume":"157","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1525-1497.2000.04329.x","article-title":"Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs","volume":"15","author":"Segal","year":"2000","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0002-9149(98)00357-9","article-title":"Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation","volume":"82","author":"Pengo","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib33","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1161\/01.STR.28.12.2382","article-title":"Warfarin use among patients with atrial fibrillation","volume":"28","author":"Brass","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2005.06.007_bib34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Impact of intensity of oral anticoagulation on stroke severity and stroke mortality in patients with non-valvular atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archinte.156.4.409","article-title":"Bleeding during antithrombotic therapy in patients with atrial fibrillation","volume":"156","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.153.13.1557","article-title":"Bleeding complications in oral anticoagulant therapy: An analysis of risk factors","volume":"153","author":"van der Meer","year":"1993","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.7326\/0003-4819-124-11-199606010-00004","article-title":"The risk for and severity of bleeding complications in elderly patients treated with warfarin","volume":"124","author":"Fihn","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib42","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1212\/WNL.59.7.977","article-title":"An assessment of guidelines for prevention of ischemic stroke","volume":"59","author":"Hart","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2005.06.007_bib43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/bmj.316.7130.509","article-title":"Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: Variation in content and implications for treatment","volume":"316","author":"Thomson","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2005.06.007_bib44","first-page":"1","article-title":"The Stroke Prevention in Atrial Fibrillation III study: Rationale, design, and patient features","volume":"6","year":"1997","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.pcad.2005.06.007_bib45","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archinte.158.12.1316","article-title":"Echocardiographic predictors of stroke in patients with atrial fibrillation","volume":"158","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","article-title":"Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials","volume":"30","author":"Hart","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2005.06.007_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-116-1-1","article-title":"Predictors of thromboembolism in atrial fibrillation, I: Clinical features of patients at risk","volume":"116","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1052-3057(10)80166-1","article-title":"Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation study","volume":"5","year":"1995","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.pcad.2005.06.007_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1161\/01.CIR.102.1.11","article-title":"Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"102","author":"Go","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib51","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib52","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jama.290.8.1049","article-title":"A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study","volume":"290","author":"Wang","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib53","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/0003-4819-128-8-199804150-00004","article-title":"Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation","volume":"128","author":"Stollberger","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-128-8-199804150-00005","article-title":"Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation","volume":"128","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(99)00489-1","article-title":"Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy","volume":"35","author":"Hart","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib56","doi-asserted-by":"crossref","first-page":"429S","DOI":"10.1378\/chest.126.3_suppl.429S","article-title":"Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Singer","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2005.06.007_bib57","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib58","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","article-title":"Ticlopidine and clopidogrel","volume":"100","author":"Quinn","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000057284","article-title":"Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB)","volume":"32","author":"Muller","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.pcad.2005.06.007_bib60","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.ahj.2004.02.008","article-title":"Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: The Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study","volume":"148","author":"Lorenzoni","year":"2004","journal-title":"Am. Heart J."},{"key":"10.1016\/j.pcad.2005.06.007_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0049-3848(87)90399-9","article-title":"Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk","volume":"48","author":"Mannucci","year":"1987","journal-title":"Thromb. Res."},{"key":"10.1016\/j.pcad.2005.06.007_bib62","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.STR.28.5.1015","article-title":"Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) investigators","volume":"28","author":"Morocutti","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2005.06.007_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: Intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb. Res."},{"key":"10.1016\/j.pcad.2005.06.007_bib64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000073849","article-title":"Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation","volume":"33","author":"Wolzt","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.pcad.2005.06.007_bib65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib66","article-title":"Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V)","author":"Halperin","year":"2003"},{"key":"10.1016\/j.pcad.2005.06.007_bib67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","article-title":"Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)","volume":"146","author":"Halperin","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.pcad.2005.06.007_bib68","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib69","author":"Desai"},{"key":"10.1016\/j.pcad.2005.06.007_bib71","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pcad.2005.06.007_bib73","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib74","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib75","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib76","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib77","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","article-title":"Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study","volume":"106","author":"Madrid","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib78","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1540-8159.2004.00645.x","article-title":"The role of angiotensin receptor blockers and\/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials","volume":"27","author":"Madrid","year":"2004","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib79","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.324.7339.699","article-title":"Use of ramipril in preventing stroke: Double blind randomised trial","volume":"324","author":"Bosch","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2005.06.007_bib80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/01.HYP.0000151324.05355.1c","article-title":"Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention For Endpoint reduction in hypertension study","volume":"45","author":"Kizer","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2005.06.007_bib81","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib82","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib83","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2005.06.007_bib84","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.amjmed.2004.04.022","article-title":"Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials","volume":"117","author":"Briel","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.pcad.2005.06.007_bib85","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1161\/01.CIR.0000015698.54752.6D","article-title":"Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: Early clinical experience","volume":"105","author":"Sievert","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2005.06.007_bib86","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.jacc.2003.12.050","article-title":"Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): Six-month echocardiographic follow-up","volume":"43","author":"Hanna","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pcad.2005.06.007_bib87","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/jama.291.14.1720","article-title":"A multicenter risk index for atrial fibrillation after cardiac surgery","volume":"291","author":"Mathew","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib88","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jama.276.4.300","article-title":"Atrial fibrillation following coronary artery bypass graft surgery: Predictors, outcomes, and resource utilization. Multicenter Study of Perioperative Ischemia Research Group","volume":"276","author":"Mathew","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2005.06.007_bib89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1067\/mhj.2003.44","article-title":"Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention","volume":"145","author":"Crystal","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.pcad.2005.06.007_bib90","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-131-7-199910050-00011","article-title":"Atrial fibrillation: The epidemic of the new millennium [editorial; comment]","volume":"131","author":"Ezekowitz","year":"1999","journal-title":"Ann. Intern. Med."}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062005000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062005000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:16:16Z","timestamp":1586564176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062005000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0033062005000356"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2005.06.007","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}